NanoViricides Announces Promising Results with NV-387 in Potentially Treating Smallpox and Mpox

NanoViricides, Inc., a leader in antiviral nanomedicines, reported significant findings regarding their drug candidate, NV-387. The studies indicate that NV-387 can combat orthopoxvirus infections, relevant to Smallpox and Mpox, via both inhalation and skin transmission. In comparative studies with tecovirimat, the approved drug for Smallpox, NV-387 demonstrated a strong potential in increasing the lifespan of mice infected with Ectromelia virus, a model for human orthopoxvirus infections.

Recent studies revealed that NV-387, when used alone or in combination with tecovirimat, extended the survival of mice significantly compared to those treated with tecovirimat alone or untreated. The results suggest that combining NV-387 with tecovirimat could be more effective than using either drug independently.

This research also implies benefits in bioterrorism scenarios where aerosolized virus dispersion could occur, showing NV-387's potential as a robust antiviral intervention. The combination of NV-387 and tecovirimat may also reduce the risk of drug resistance by preventing virus escape through mutations.